Foundayo
FDA requests further safety data from Eli Lilly on Foundayo's liver injury risks
The FDA has requested additional safety information from Eli Lilly regarding liver injury concerns linked to Foundayo. This step indicates heightened regulatory scrutiny even after the drug's recent approval.
Surge in Online Searches and Policy Changes Highlight Growing GLP-1 Weight-Loss Drug Concerns
Following a Super Bowl commercial, online searches for GLP-1 weight-loss drugs have skyrocketed, raising safety concerns over unverified sales. Simultaneously, some US states are cutting Medicaid coverage, complicating access for low-income users.
FDA Approves Eli Lilly's Foundayo Oral GLP-1 for Weight Management
The FDA has approved Eli Lilly's new oral GLP-1 weight-loss medication, Foundayo, for adults with obesity or overweight. This approval introduces a convenient pill option that could significantly shift weight management treatments and market dynamics.
Eli Lilly’s FDA-Approved Obesity Drug Foundayo Challenges Wegovy's Market Lead
Eli Lilly’s FDA-approved oral obesity drug Foundayo offers a convenient alternative to Wegovy, intensifying competition in the weight-loss medication market and expanding patient options.